This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
Palliative Performance Scale Predicts Survival in Patients with Bone Metastasis Undergoing Radiotherapy
by
Gina Hennig
Gina Hennig ,
Emma Thrandorf
Emma Thrandorf ,
Dirk Vordermark
Dirk Vordermark and
Jörg Andreas Müller
Jörg Andreas Müller *
Department of Radiation Oncology, University Hospital Halle (Saale), D-06120 Halle (Saale), Germany
*
Author to whom correspondence should be addressed.
Submission received: 1 December 2025
/
Revised: 17 December 2025
/
Accepted: 22 December 2025
/
Published: 24 December 2025
Simple Summary
Accurately estimating survival is crucial for guiding treatment decisions in patients receiving palliative radiotherapy. In this retrospective real-world study, we evaluated the prognostic value of the Palliative Performance Scale (PPS) in 153 patients treated with radiotherapy for bone metastases. We found that functional status, as measured by PPS, was strongly associated with overall survival, with patients showing a PPS of 60% or higher living significantly longer. Completion of the planned radiotherapy course was also a key predictor of improved survival, even in a frail population. In contrast, PPS did not predict discharge destination after treatment, suggesting that post-treatment care needs are influenced by additional social and organizational factors. These findings support the routine use of PPS to aid prognostication and treatment planning in palliative radiotherapy.
Abstract
Background: Accurate prognostication is essential for clinical decision-making in palliative radiotherapy (RT). The Palliative Performance Scale (PPS) is a validated tool for assessing functional status and estimating survival in palliative care, yet its prognostic value in patients receiving palliative RT for bone metastases remains insufficiently explored. This study aimed to evaluate the association between PPS and overall survival (OS) in a real-world cohort of cancer patients undergoing palliative RT. Methods: This retrospective, single-center study included 153 patients who received palliative RT for bone metastases between 2021 and 2025 at the Department of Radiation Oncology, University Hospital Halle (Saale), Germany. Clinical, demographic, and treatment data were extracted from institutional databases. The primary endpoint was OS, defined as the time from the end of RT to death. Univariable and multivariable Cox proportional hazards regression models were used to identify prognostic factors associated with OS, including PPS, sex, age, marital status, BMI, Charlson Comorbidity Index (CCI), and RT completion. Due to violation of the proportional hazards assumption, PPS (<60% vs. ≥60%) was used as a stratification factor in the final Cox model. Logistic regression was performed to explore predictors of discharge to home. Results: The median OS for the entire cohort was 108 days (3.6 months; 95% CI 78–143 days). Male sex (HR 1.61, 95% CI 1.06–2.46, p = 0.027) and older age (HR 0.98, 95% CI 0.96–1.00, p = 0.050) were associated with shorter survival, whereas completion of the prescribed RT course was strongly associated with improved OS (HR 0.06, 95% CI 0.03–0.12, p < 0.001). Patients with PPS ≥60% had significantly better survival compared to those with lower PPS (HR 0.62, 95% CI 0.41–0.93, p = 0.021). After stratification by PPS, no violation of the proportional hazards assumption was detected (global p = 0.55). The stratified model confirmed that male sex, age, and RT completion remained independent predictors of survival. No significant predictors were identified for discharge destination in logistic regression analysis. Conclusions: The PPS is a valuable prognostic tool for patients receiving palliative RT for bone metastases. A PPS of ≥60% was associated with prolonged survival, supporting its use in clinical prognostication and treatment planning. Completion of RT emerged as a strong independent predictor of survival, underscoring the importance of treatment adherence even in palliative settings. Stratification by PPS further improved model validity and prognostic accuracy.
Share and Cite
MDPI and ACS Style
Hennig, G.; Thrandorf, E.; Vordermark, D.; Müller, J.A.
Palliative Performance Scale Predicts Survival in Patients with Bone Metastasis Undergoing Radiotherapy. Cancers 2026, 18, 61.
https://doi.org/10.3390/cancers18010061
AMA Style
Hennig G, Thrandorf E, Vordermark D, Müller JA.
Palliative Performance Scale Predicts Survival in Patients with Bone Metastasis Undergoing Radiotherapy. Cancers. 2026; 18(1):61.
https://doi.org/10.3390/cancers18010061
Chicago/Turabian Style
Hennig, Gina, Emma Thrandorf, Dirk Vordermark, and Jörg Andreas Müller.
2026. "Palliative Performance Scale Predicts Survival in Patients with Bone Metastasis Undergoing Radiotherapy" Cancers 18, no. 1: 61.
https://doi.org/10.3390/cancers18010061
APA Style
Hennig, G., Thrandorf, E., Vordermark, D., & Müller, J. A.
(2026). Palliative Performance Scale Predicts Survival in Patients with Bone Metastasis Undergoing Radiotherapy. Cancers, 18(1), 61.
https://doi.org/10.3390/cancers18010061
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.